The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer.
E. Gabriela Chiorean
Research Funding - Celgene
Scott Whiting
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Gary Binder
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
George Dranitsaris
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Victoria Manax
Employment or Leadership Position - Celgene
Stock Ownership - Celgene